Skip to main content

Drug Interactions between apomorphine and solriamfetol

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

apomorphine solriamfetol

Applies to: apomorphine and solriamfetol

MONITOR: Coadministration of solriamfetol with other drugs that increase dopamine levels or that bind directly to dopamine receptors may increase the risk of dopaminergic-related adverse effects. The mechanism of the interaction has not been reported, but it may involve synergistic or additive central dopaminergic effects. This interaction has not been evaluated clinically.

MANAGEMENT: Caution is advised if solriamfetol is administered concomitantly with other dopaminergic drugs. Dosage adjustments and close patient monitoring should be considered whenever solriamfetol is used with other dopaminergic drugs.

References (1)
  1. (2019) "Product Information. Sunosi (solriamfetol)." Jazz Pharmaceuticals

Drug and food interactions

Moderate

apomorphine food

Applies to: apomorphine

GENERALLY AVOID: Alcohol and apomorphine may have additive hypotensive and sedative effects. Coadministration of 0.6 or 0.3 g/kg of ethanol with apomorphine in healthy subjects resulted in greater decreases in blood pressure compared to apomorphine alone. The mean largest decrease (the mean of each subject's largest drop in blood pressure measured within 6 hours after apomorphine administration) in standing systolic and diastolic blood pressure was 6.7 and 8.4 mmHg, respectively, with apomorphine alone. When coadministered with 0.6 g/kg of ethanol (equivalent to approximately 3 standardized alcohol-containing beverages), the mean largest decrease in standing systolic and diastolic blood pressure was 11.3 and 12.6 mmHg, respectively (standing systolic and diastolic blood pressure decreased by as much as 61 and 51 mmHg, respectively, in this group). When coadministered with 0.3 g/kg of ethanol, the mean largest decrease in standing systolic and diastolic blood pressure was 8.4 and 7.1 mmHg, respectively.

MANAGEMENT: Patients should be advised to avoid consumption of alcohol during apomorphine treatment.

References (5)
  1. (2022) "Product Information. Apokyn (apomorphine)." US WorldMeds LLC
  2. (2022) "Product Information. Kynmobi (apomorphine)." Sunovion Pharmaceuticals Inc
  3. (2023) "Product Information. Dacepton (apomorphine)." Ever Pharma UK Ltd
  4. (2024) "Product Information. aPomine Intermittent (apomorphine)." Pfizer Australia Pty Ltd, 1.1
  5. (2024) "Product Information. Movapo (apomorphine)." Stada Pharmaceuticals Australia Pty Ltd

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer